VCNX
Price:
$1.18
Market Cap:
$3.16M
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical devel...[Read more]
Industry
Biotechnology
IPO Date
2018-08-09
Stock Exchange
NASDAQ
Ticker
VCNX
According to Vaccinex, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 311.44K. This represents a change of -94.93% compared to the average of 6.14M of the last 4 quarters.
The mean historical Enterprise Value of Vaccinex, Inc. over the last ten years is 35.32M. The current 311.44K Enterprise Value has changed -11.84% with respect to the historical average. Over the past ten years (40 quarters), VCNX's Enterprise Value was at its highest in in the June 2018 quarter at 91.39M. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.
Average
35.32M
Median
29.57M
Minimum
3.00M
Maximum
63.49M
Discovering the peaks and valleys of Vaccinex, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 345.63%
Maximum Annual Enterprise Value = 63.49M
Minimum Annual Increase = -85.90%
Minimum Annual Enterprise Value = 3.00M
Year | Enterprise Value | Change |
---|---|---|
2023 | 3.00M | -85.90% |
2022 | 21.25M | -1.79% |
2021 | 21.64M | -42.29% |
2020 | 37.50M | -37.18% |
2019 | 59.70M | 345.63% |
2018 | 13.40M | -78.90% |
2017 | 63.49M | 1.39% |
The current Enterprise Value of Vaccinex, Inc. (VCNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.30M
5-year avg
28.62M
10-year avg
35.32M
Vaccinex, Inc.’s Enterprise Value is less than Protara Therapeutics, Inc. (130.41M), less than Monopar Therapeutics Inc. (110.36M), less than Miromatrix Medical Inc. (90.06M), less than Surrozen, Inc. (10.29M), less than First Wave BioPharma, Inc. (2.80M), greater than Salarius Pharmaceuticals, Inc. (-807852.00), less than SAB Biotherapeutics, Inc. (33.19M), less than GeoVax Labs, Inc. (12.73M), less than ZIVO Bioscience, Inc. (0), less than Theseus Pharmaceuticals, Inc. (78.24M), less than Erasca, Inc. (138.26M), less than Forte Biosciences, Inc. (710.66M), less than Applied Molecular Transport Inc. (12.44M), greater than RenovoRx, Inc. (-5743713.00), less than Anebulo Pharmaceuticals, Inc. (21.40M), less than Eledon Pharmaceuticals, Inc. (40.61M), less than null (248.84M),
Company | Enterprise Value | Market cap |
---|---|---|
130.41M | $177.43M | |
110.36M | $116.38M | |
90.06M | $92.95M | |
10.29M | $39.78M | |
2.80M | $5.99M | |
-807852.00 | $2.15M | |
33.19M | $37.84M | |
12.73M | $21.33M | |
0 | $78.37M | |
78.24M | $181.50M | |
138.26M | $726.61M | |
710.66M | $28.80M | |
12.44M | $11.01M | |
-5743713.00 | $30.96M | |
21.40M | $42.01M | |
40.61M | $255.09M | |
248.84M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaccinex, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vaccinex, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Vaccinex, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Vaccinex, Inc. (VCNX)?
What is the 3-year average Enterprise Value for Vaccinex, Inc. (VCNX)?
What is the 5-year average Enterprise Value for Vaccinex, Inc. (VCNX)?
How does the current Enterprise Value for Vaccinex, Inc. (VCNX) compare to its historical average?